Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

ated to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Financial tables follow

                                      InterMune, Inc.
               PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                   (unaudited, in thousands, except per share amounts)

                                      Three Months Ended      Six Months Ended
                                        
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp Biopharmaceutical,s ... ZMapp™ antibody therapeutic to fight the Ebola outbreak ... and time-consuming the production of pharmaceuticals can be, ... publisher said that while some may be taken ... compound, those with industry knowledge are well aware ...
(Date:10/20/2014)... 2014  GenVec, Inc. (NASDAQ: GNVC ) today ... from its board of directors effective on October 24, 2014.  ... served as its chairman from June 2006 to November 2013.  ... Corporate Governance and Audit Committees of the board.  ... of dedicated service to GenVec, and its stockholders," said ...
(Date:10/19/2014)... Latin American hardware encryption display market report defines and ... forecast of revenue. This market was valued at $165.0 ... million by 2018, at a CAGR of 70.3% from ... the Latin American hardware encryption market report to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Speech Analytics ... in Asia-Pacific with analysis and forecast of revenue. This ... 2014 to $208 million by 2019, at a Compound ... 2019. , Browse through the TOC of the Asia-Pacific ... the in-depth analysis provided. It also provides a glimpse ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... , SAN FRANCISCO , Feb. 1 ... as a placement agent in GenVec, Inc.,s (Nasdaq: GNVC ) ... common stock, and warrants to purchase 4.2 million shares of common ...   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with the Merriman ...
... ... Health Canada Inspection and Compliance with European Directive for Manufacture and Testing of Drug ... ... Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced ...
... , FORT LAUDERDALE, Fla. , Feb. 1 ... EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrated good safety ... late stent thrombosis at one year in patients with ... intervention (PCI) and implantation of the company,s Genous Bio-engineered ...
Cached Biology Technology:Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 2Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 3OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 3
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
(Date:10/15/2014)... an unexpected extent. The outbreak does not follow the ... a new disease dynamic in regions, where it has ... National Academy of Sciences Leopoldina, acatech – the German ... the German Academies of Sciences and Humanities have presented ... the statement the academies call for the following consequences ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... woodpecker is alive and well in Arkansas, USA may ... published today in the open access journal BMC Biology ... Woodpecker Campephilus principalis could be another native woodpecker species. ... footage from April 2004 of the supposed Ivory-billed Woodpecker ...
... found naturally in the gut is the basis of a ... under the Wellcome Trust's Seeding Drug Discovery initiative. The drug ... experts, Professor Steve Bloom at Imperial College London's Hammersmith Hospital ... by obesity in England alone, so there is a clear ...
... Pharmacology at the University of California, San Diego (UCSD) ... over the past few years, which has led him ... and genes, we have started to put together unexpected ... twins provides scientists with data on traits that are ...
Cached Biology News:A case of mistaken identity for the ivory-billed woodpecker? 2Natural gut hormone offers hope for new obesity drug 2Twin studies reveal genetic components leading to cardiac and kidney disease 2Twin studies reveal genetic components leading to cardiac and kidney disease 3
... Combination inline heater plus multi-channel focal drug ... wash-out with a high-flow bath line while ... through the Perfusion Pencil.® Steady 37°C at ... bath line and tip. Advanced ...
...
... human angiogenin expressed in ... form: Lyophilized from a 0.2 ... buffered saline. Titertest method: ... Titertest values: capture ELISA 1-2 ...
Mouse Amphiregulin MAb (Clone 206220)...
Biology Products: